NEWS FLASH

The UCSD/UCLA DERC is RENEWED for Five Years

We are pleased to announce that our UCSD/UCLA Diabetes Endocrinology Research Center competitive renewal application was successful and that the grant was approved and funded for a new five-year period. We are currently in the first year of this new project period, and this Newsletter outlines some of the new developments and alignments of the current Center grant. Most importantly, the original PI, Dr. Willa Hsueh, left UCLA a year ago to take a new position in Houston. As a result, Dr. Jerrold Olefsky has now assumed responsibility as PI of the overall Center grant for its current five-year project period. Since the overhead rates of the two Institutions are comparable, this is mainly an administrative issue with no real budgetary impact and simply affects where bills are sent and where the checks are issued. On a more substantive subject, the new Center grant has all of the original Cores and two programs. In addition, as part of our continuation grant, we received funding for a new Core headed by Peter Tontonoz, called the “Inflammation Core”.

Core A: Transgenic and Knockout Mouse Core, Director: Pamela Mellon
Core B: Mouse Phenotyping Core, Director: Rajendra Tangirala
Core C: Transcriptional Genomics Core, Director: Christopher Glass
Core D: Human Genetics Core, Director: Jerome Rotter
Core E: Inflammation Core, Director: Peter Tontonoz

NEW in 2008, SEE PAGE 3
Pilot & Feasibility Program, Director: Pinchas Cohen

2009 P&F Announcement, SEE PAGE 4
Academic Enrichment Program, Director: Jerrold Olefsky

Meeting Announcement: SEE PAGE 2

All of the original services offered by the DERC cores are still provided and these are now supplemented by a new list of services and resources offered through the Inflammation Core.

Sincerely yours,

Jerrold Olefsky, M.D., UCSD DERC P.I.
MEETING ANNOUNCEMENT

Clinical Investigation Institute/Nature Medicine

Bench to Bedside: Metabolism

October 8-10, 2009

As part of our Enrichment activities, the DERC will help host a scientific meeting co-sponsored by Nature Medicine and UCSD next Fall in La Jolla. This Nature Medicine meeting is focused on Diabetes and Metabolism and begins the evening of October 8th, ending at Noon at Saturday October 10th. On Saturday afternoon, (October 10th), the DERC will put on its own scientific presentations, based on the work of P&F recipients. The program for this meeting is outstanding (see attached) and all DERC members, including all P&F recipients, are encouraged to attend the full meeting starting Thursday evening. The Western region DERCs (Baylor, UCSD/UCLA, University of Colorado, and University of Washington) have organized into a subgroup and through the Regional DERC Director’s committee, we have already arranged for P&F recipients from the other Western Centers to attend this meeting. Speakers Include:

- Michael Brown (U Texas)
- Helen Hobbs (U Texas)
- Gokhan Hotamisligil (Harvard)
- Peter Libby (Harvard)
- Michael Karin (UCSD)
- Steve Shoelson (Joslin Diabetes Center)
- Paresh Dandona (SUNY Buffalo)
- Gerry Shulman (Yale)
- Ira Goldberg (Columbia)
- Phil Scherer (U Texas)
- Barbara Kahn (Harvard)
- Chris Newgard (Duke)
- Tony Lam (Toronto)
- Zofia Zukowska (Georgetown)
- Daniel Drucker (Toronto)
- David Cummings (U Wash)
- Francesco Rubino (Cornell Medical Center-NYC)

Hilton La Jolla Torrey Pines
10950 North Torrey Pines Road, La Jolla, California
The Inflammation CORE
CORE Director: Peter Tontonoz, M.D., Ph.D.
Professor of Pathology and Laboratory Medicine

The Inflammation Core is an outgrowth of the interests of our DERC membership in mechanisms of inflammation that play roles in the development and progression of both metabolic and cardiovascular diseases. The objective of this Core is to provide state-of-the-art assays and techniques to investigators focusing on the role of inflammation in the settings of obesity, insulin resistance and diabetes. The Inflammation Core will aid DERC investigations by providing:

1. Standardized, accurate, precise and quality-controlled analyses.
2. Consistent, high-quality human monocyte preparations.
3. High-throughput profiling of nuclear receptor expression.
4. Consultation on available assays, experimental design and data interpretation.
5. Instruction on how to perform Core assays at user request.

DERC Inflammation Core services

<table>
<thead>
<tr>
<th>Service</th>
<th>Non DERC Members</th>
<th>DERC Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luminex protein assay: Human, Mouse</td>
<td>$300 per assay</td>
<td>$150 per assay</td>
</tr>
<tr>
<td>Rat Cytokine, Chemokine, Adipokine &amp; CVD1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luminex mRNA assays</td>
<td>$300 per assay</td>
<td>$150 per assay</td>
</tr>
<tr>
<td>HMW/LMW Human adiponectin</td>
<td>$350</td>
<td>$175</td>
</tr>
<tr>
<td>Nuclear receptor profiling</td>
<td>$150</td>
<td>$75</td>
</tr>
</tbody>
</table>

Multiplex assays offered through the Core are listed below:

- **Human Adipokine**: Adiponectin (total), PAI-1, Resistin
- **Mouse Adipokine**: IL-6, Insulin, Leptin, MCP-1, PAI-1, Resistin, TNF-α
- **Rat Adipokine**: IL-1β, IL-6, Insulin, Leptin, MCP-1, PAI-1, TNF-α
- **Human CVD1**: MMP-9, MPO, PAI-1 (total), sE-selectin, sICAM-1, sVCAM-1
- **Mouse CVD1**: MMP-9, PAI-1 (total), sE-selectin, sICAM-1, sVCAM-1
- **Human Cytokines/Chemokines**: IL-1α, IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, EGF, Eotaxin, Fractalkine, G-CSF, GM-CSF, IFNγ, IP-10, MCP-1, MIP-1α, MIP-1β, RANTES, sCD40L, TGFα, TNFα, VEGF
- **Mouse Cytokine / Chemokine**: IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, G-CSF, GM-CSF, IFNγ, IP-10, KC, MCP-1, MIP-1α, RANTES, TNFα
- **Rat Cytokines/Chemokines**: IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p70), IL-13, IL-17, IL-18, Eotaxin, G-CSF, GM-CSF, GRO/KC, IFNγ, IP-10, Leptin, MCP-1, MIP-1α, RANTES, TNFα, VEGF

Core Contact: Rima Boyadjian, 310-206-4622, rboyadjian@mednet.ucla.edu
**DERC P&F 2009 Grant ANNOUNCEMENT**

**Applications DUE March 6th 2009**

**Pilot and feasibility projects in Endocrinology and Diabetes**

As part of the recently renewed UCSD/UCLA DERC grant, a mechanism to fund innovative new projects that will explore the feasibility of novel testable concepts and enhance the endocrine/diabetes research scope within the institutions is again available. The Pilot and Feasibility grant program is putting out a request for applications that will support 4-5 grantees at approximately $30,000-$40,000 per year. A special emphasis on promoting promising junior faculty involved with diabetes research is key to the UCSD/UCLA P&F mission. It is expected that P&F studies will generate preliminary data that will be used by these investigators in diabetes/endocrinology-related RO1 applications in the years following their award.

**P&F grant format**

A strict requirement for the grant format will be implemented. Failure to meet this requirement will lead to an administrative disqualification of the proposal. The P&F grant applications should include:

(a) A face page with the title of the grant, the name, email, academic title, and department and institution of the PI, the names of any additional personnel and collaborators and a 200 word abstract.

(b) Biosketches for the PI and other key personnel.

(c) The scientific proposal (5-page limit).

(d) References.

The entire grant must be submitted as a single emailed pdf file less than 2 megabite in size. If the grant includes high-resolution images, these must be reduced to meet the size requirement. Failure to provide a single pdf file or a file that is too big will result in disqualification. No budget is required, but the scope of the work should be appropriate for 1-year project and the funds cannot be used for the PI salary.

**Eligibility**

All eligible investigators must have faculty appointments at UCLA or UCSD and be independent investigators. To be eligible for a P&F grant you need to be eligible to submit an RO1 as a PI at the end of the grant period. A joint appointment at an affiliated institution is allowed. Investigators eligible for pilot and feasibility funding generally will be expected to fall into three categories:

1. **(Category 1) New investigators without current or past non-mentored NIH research support as a principal investigator (current or past support from other sources being modest).**
2. **(Category 2) Established investigators with no previous work in diabetes that wish to apply their expertise to a problem in this area.**
3. **(Category 3) Established investigators in diabetes/endocrinology research who propose testing innovative ideas that represent clear departure from ongoing research interests.**

**Interactions with other DERC components**

It is expected that junior faculty will be able to rely on the advice and support of a senior DERC investigator and will have a priority access to DERC Cores, including an opportunity to discuss their projects in depth with the core directors in order to receive maximum benefits from their services. Similarly, investigators with no previous experience in diabetes/endocrinology research will be expected to have a DERC collaborator. P&F grantees will be encouraged and expected to utilize DERC core resources.

**Final report and presentation at the annual retreat**

A report on each pilot and feasibility study conducted will be requested from investigators at the end of the study period and an update will be requested yearly for four years after the completion of the award. These brief reports will contain professional career status at the time of the award and at the time of the report; an overview of the project including its significance and salient results; a list of resulting publications; and peer-reviewed subsequent funding in the same or related areas. Funded P&F investigators will be expected to attend the annual DERC retreat as well as in a meeting of Regional P&F awardees, and present the results of their work in the year immediately following their award. Travel to these meetings will be charged to the individual P&F awards.

**Notification procedure:**

After approval of the funding decisions by the DERC executive committee, funded and unfunded investigators will be notified and, when appropriate, a brief summary of the reviews will be sent to them by email (not a detailed critique).